January 07, 2012

Stock : Cadila Healthcare Ltd ~ Sector : Healthcare

Cadila Healthcare Ltd has informed BSE regarding a Press Release dated January 06, 2012 titled "Microtaix and Zydus Cadila reach agreement to market Urokinase, a critical care therapy in North America". Microbix Biosystems Inc., a biotechnology company commercializing novel technologies and Zydus Cadila, India, today reported that they have signed a Letter of Intent to market the Thrombolytic drug, Urokinase in the North American markets. The estimated market size for Urokinase use in the U.S. alone is expected to touch $400 million by 2020 between three indications: pulmonary embolism, catheter clearance and catheter prophylaxis. The same active pharmaceutical ingredient can be used in new and even larger indications in oncology and ophthalmology.